Weekly Spotlight - 14.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Diagnosing ASMD and Niemann-Pick Disease from Blood Smears

The article discusses diagnosing acid sphingomyelinase deficiency (ASMD) and Niemann-Pick disease type C using bone marrow and blood smears. It highlights the importance of identifying foamy histiocytes and vacuolated lymphocytes in these smears, aiding in early diagnosis and treatment. This approach offers hope for improved patient outcomes.

Lysoway's New Hope for Neurological and Age-Related Diseases

Lysoway Therapeutics Inc. has developed new activators for mucolipin-1, offering hope for treating various conditions like age-related macular degeneration, Alzheimer's, and muscular dystrophy. These advancements could significantly improve patient outcomes, providing a brighter future for those affected by these challenging diseases. The potential impact is truly promising.

Niemann-Pick Disease Type C: Promising Clinical Trials and Therapies

The Niemann-Pick Disease Type C pipeline is advancing with over 15 therapies in development by key companies like Actelion and Cyclo Therapeutics. Recent trials show promising results, with FDA reviews ongoing. This progress offers hope for improved treatments, addressing a rare genetic disorder affecting lipid metabolism in cells.

Zevra Validates Swallow Domain in Niemann-Pick Disease Severity Scale

Zevra Therapeutics presented findings at the Child Neurology Society Meeting, validating the swallow domain's role in Niemann-Pick Disease Type C treatment. The revised scoring system accurately reflects changes in swallowing function, showing a significant treatment difference with arimoclomol. This offers hope for improved patient outcomes.